Asperger syndrome cost-effectiveness of therapy

Asperger Syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Asperger Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Behavioral Therapy
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Asperger syndrome cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Asperger syndrome cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Asperger syndrome cost-effectiveness of therapy
CDC on Asperger syndrome cost-effectiveness of therapy
Asperger syndrome cost-effectiveness of therapy in the news
Blogs on Asperger syndrome cost-effectiveness of therapy
Directions to Hospitals TreatingAsperger syndrome
Risk calculators and risk factors for Asperger syndrome cost-effectiveness of therapy

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Based on a prevelance of 1.1 % for autism spectrum disorder (ASD) in the US, the economic burden for ASD has been estimated to be $268.2991 billion (1.467% of GDP) and $460.8002 billion (1.649% of GDP) in 2015 and 2025 respectively.

Cost-Effectiveness of Therapy

Based on a prevelance of 1.1 % for autism spectrum disorder (ASD) in the US, the economic burden for ASD has been estimated to be $268.2991 billion (1.467% of GDP) and $460.8002 billion (1.649% of GDP) in 2015 and 2025 respectively.